Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preclinical developments in type 2 diabetes.

James M Lenhard1, William K Gottschalk

  • 1Department of Metabolic Diseases, GlaxoSmithKline Inc, 5 Moore Drive, Research Triangle Park, NC 27709, USA. jml29514@gsk.com

Advanced Drug Delivery Reviews
|October 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>TOMM40</i> '523' genotype induces sex- and tissue- specific differences in cholesterol and triglyceride levels in an <i>APOE-TOMM40</i> humanized mouse model.

bioRxiv : the preprint server for biology·2026
Same author

The APOE-TOMM40 Humanized Mouse Model: Characterization of Age, Sex, and PolyT Variant Effects on Gene Expression.

Journal of Alzheimer's disease : JAD·2023
Same author

APOE, TOMM40, and sex interactions on neural network connectivity.

Neurobiology of aging·2021
Same author

Spousal Influence on Diabetes Self-care: Moderating Effects of Distress and Relationship Quality on Glycemic Control.

Annals of behavioral medicine : a publication of the Society of Behavioral Medicine·2020
Same author

Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.

American journal of physiology. Gastrointestinal and liver physiology·2019
Same author

The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2018
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

New type 2 diabetes treatments are exploring novel targets like ACC2, IKK-beta, DPP-IV, and GLP-1R to improve insulin action and glucose metabolism, addressing limitations of current therapies.

Area of Science:

  • Endocrinology and Metabolism
  • Molecular Biology
  • Pharmacology

Background:

  • Type 2 diabetes involves insulin resistance in muscle and fat, impaired pancreatic beta-cell function, and increased liver glucose production.
  • Existing pharmacotherapies do not fully correct the underlying metabolic dysfunctions.
  • There is a critical need for novel therapeutic targets to address these defects.

Purpose of the Study:

  • To review recent research on novel molecular targets for type 2 diabetes treatment.
  • To explore targets that enhance insulin sensitivity, promote glucose and fat breakdown, reduce hepatic glucose output, and improve beta-cell function.
  • To discuss the potential of acetyl-CoA carboxylase 2 (ACC2), I kappa kinase (IKK) beta, dipeptidyl peptidase IV (DPP-IV), and glucagon-like peptide-1 receptor (GLP-1R) as therapeutic targets.

Related Experiment Videos

Main Methods:

  • Literature review of recent scientific developments.
  • Focus on molecular targets involved in glucose and lipid metabolism.
  • Analysis of pathways related to insulin action and secretion.

Main Results:

  • Identification of ACC2, IKK-beta, DPP-IV, and GLP-1R as promising targets.
  • These targets offer potential to enhance insulin action in peripheral tissues.
  • They may also stimulate catabolism, reduce glucose production, and improve beta-cell function.

Conclusions:

  • Novel targets such as ACC2, IKK-beta, DPP-IV, and GLP-1R represent a promising frontier in type 2 diabetes pharmacotherapy.
  • Further research into these targets could lead to more effective treatments for metabolic defects.
  • Targeting these pathways may offer a comprehensive approach to managing type 2 diabetes.